So they met with the board twice in June and twice in August to decide what would come next. The company recently began a phase 2/3 clinical study with its partner, GlaxoSmithKline, evaluating an antibody therapy targeting COVID-19. BioNTech was only founded in 2008. Shares fell rough­ly 9% on both the Nas­daq $BGNE and the Hong Kong stock ex­change (06160) on al­le­ga­tions that the com­pa­ny faked sales of the Cel­gene drugs it’s in charge of mar­ket­ing in Chi­na, in­vest­ed in bo­gus man­u­fac­tur­ing sites, and over­spent on wages for R&D staff. Bill Gates criticized the federal government's handling of the virus and its subsequent vaccination plan. Tim Mur­ray, au­thor of the re­port, fur­ther ac­cused ex­ecs of “pump­ing and dump­ing,” talk­ing up BeiGene’s stand­ing with Chi­nese drug reg­u­la­tors and po­ten­tial for its drugs while covert­ly sell­ing off their own stock. The Keytruda-Lenvima combo nailed its primary progression-free survival and OS endpoints against placebo in a Phase III study in advanced, metastatic or recurrent endometrial cancer patients receiving chemotherapy, according to data presented Friday at the virtual Society of Gynecologic Oncology annual meeting. “BeiGene re­mains fo­cused on its mis­sion to build a bio­phar­ma­ceu­ti­cal com­pa­ny that will pro­vide the high­est qual­i­ty ther­a­pies to the great­est num­ber of pa­tients around the world.”. For investors who are more risk-averse, Pfizer is the best pick. … In a CNBC interview, he said, "The … Bill Gates predicts when the next pandemic will arrive Covid-19 vaccines developed by Pfizer and BioNTech are awaiting FDA approval but the tech billionaire warns that another virus is … However, this investment wasn't initiated because of Pfizer's coronavirus program. The company expects to report initial results next month from a late-stage study of BNT162b2, the COVID-19 vaccine candidate that it's developing with BioNTech (NASDAQ: BNTX). Das Mainzer Unternehmen Biontech erhält mindestens 55 Millionen US-Dollar von der Bill-Gates-Stiftung. Have you ever wondered how much these essential workers make? Now the New Jersey drugmaker’s big C-suite shakeup continues, as Mike Nally steps away from the chief marketing job at the pharma giant. BioNTech signed an agreement with the Bill & Melinda Gates Foundation in September, 2019, just before announcement in Wuhan China of the Novel Coronavirus and just before BioNTech made its stock market debut. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. The Gates Foundation was one of the lead investors in Vir Biotechnology (NASDAQ: VIR) at the biotech's launch in late 2016 and early 2017. Unlock this story instantly and join 104,300+ biopharma pros reading Endpoints daily — and it's free. BioN­Tech part­ners with Bill and Melin­da Gates Foun­da­tion, scor­ing $55M eq­ui­ty in­vest­ment; BeiGene brush­es off short at­tack. → No­var­tis $NVS is palm­ing off a Chi­na-based unit for $790 mil­lion yuan (about $110.5 mil­lion), ac­cord­ing to a Wednes­day re­port by Dow Jones. Then chief executive Ken Frazier laid out plans to hit the exit in June. Zusammen mit der Gates-Stiftung will Biontech HIV- und Tuberkulose-Impfstoffe erforschen. But the pharma instead chose CFO Robert Davis, a four-year Merck veteran with a decorated résumé, including time served as EVP of global services and CFO at Baxter and 14 years in the ranks at Eli Lilly. Tags: investing, stock market, Pfizer, BioNTech, Moderna, Bill Gates, global economy, money, Stock Market Today. BioNTech inks agreement with Gates Foundation to develop HIV and TB programmes. In addition, the biotech is conducting preclinical studies of an inhaled therapy targeting COVID-19. → Less than two months af­ter Ger­man biotech BioN­Tech raised a her­culean $325 mil­lion in an up­sized round of fi­nanc­ing — the Bill and Melin­da Gates Foun­da­tion have signed a pact with the com­pa­ny, mak­ing an ini­tial eq­ui­ty in­vest­ment of $55 mil­lion to de­vel­op vac­cine and im­munother­a­py can­di­dates to pre­vent HIV and tu­ber­cu­lo­sis. But the foundation hasn't just handed money over to drugmakers; it's also invested in a few of them. In addition, the Gates Foundation agreed to provide separate funding for several projects to develop vaccines based on CureVac's messenger RNA (mRNA) platform. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said Friday that it will restart its onsite inspections of drug manufacturing sites on March 29. Join our new commenting forum. La Banca europea per gli investimenti e la società di immunoterapia BionTech hanno firmato un accordo di finanziamento da 100 milioni di euro per sostenere lo sviluppo di BNT162, il programma dell’impresa per lo sviluppo di un vaccino contro la Covid-19. Should you save for retirement or pay down debt? Please note the magic link is Damit sollen Immuntherapien gefördert werden. The Bill & Melinda Gates Foundation has reportedly invested £41.8million in their current company BioNTech. The regulator also said it will ensure limited face-to-face interactions. BMS announced Friday that the agency has accepted its NDA pitch, scheduling a Jan. 28, 2022 PDUFA date for the experimental drug mavacamten. Die Bill- und Melinda-Gates Stiftung hat die Mainzer Biotechfirma Biontech investiert. The Motley Fool owns shares of and recommends Microsoft. We'll e-mail you a link to set a new password. If you're already an Endpoints subscriber, enter your email below for a The company is currently evaluating its mRNA COVID-19 vaccine in early stage clinical studies. The Bill & Melinda Gates Foundation is among the donors to have invested in the company, giving $55 (£41.8) million to aid BioNTech’s work, which also includes HIV and tuberculosis programmes. Die Gates-Stiftung investiert dazu zunächst 55 Millionen Dollar (rund 50 Millionen Euro) in Biontech. The plant, which was opened a decade ago, was sold to Chi­na’s Zhe­jiang Ji­uzhou, ex­clud­ing the Swiss drug­mak­er’s tech­nol­o­gy and drug-de­vel­op­ment as­sets. The billionaire Microsoft cofounder and his wife Melinda have been vocal proponents of fighting infectious diseases for decades. In September 2019, BioNTech received an equity investment of US$55 million from the Bill & Melinda Gates Foundation, with the option of doubling that investment amount at … The FDA on Friday approved J&J’s S1P1 receptor modulator ponesimod to treat relapsing multiple sclerosis, the drugmaker said. Video: Jim Cramer on Johnson & Johnson entering phase 3 trial for coronavirus vaccine (CNBC), How you can save $1 million for retirement, How much the most populous states pay mail carriers, Creepy ways your company can spy on you while you work from home, Major companies suspend social media advertising over online hate speech, This bookshop survived earthquakes and recessions. If it proved successful, it could return them to the perch they had lost in 2017, when a Bristol Myers Squibb-partnered drug flopped and tanked their shares. In the disease, a mutation in proteins forces the heart to exert more effort and squeeze more, blocking the outflow of blood and thickening muscle. Das 2008 gegründete Unternehmen sitzt in Mainz-Oberstadt und beschäftigte Anfang 2019 rund 850 Mitarbeiter. Show full articles without "Continue Reading" button for {0} hours. The foundation's goal with this investment was to work with BioNTech to develop vaccines and immunotherapies for preventing HIV and tuberculosis (TB) infection. The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. Stellvertretende Redaktionsleiterin Mainz. If all goes well, BNT162b2 could very well become the first coronavirus vaccine available to Americans. Von Maike Hessedenz. In a CNBC interview, he said, "The only vaccine that, if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer. También de ser una de las que más sabe de enfermedades (especialmente infecciosas) y como combatirlas. The program at the centerpiece of Bristol Myers Squibb’s buyout of MyoKardia just got one step closer to gaining potential FDA approval. BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs -- Bill & Melinda Gates Foundation invests $55 million in an … When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. That's right -- they think these 10 stocks are even better buys. In the summer of 2020, you could get a share of Five Prime Therapeutics for less than a latte, but the company’s leadership knew that could soon change. The two companies are farther along in clinical testing with their coronavirus vaccine program than CureVac and Vir. VIR-7832 could potentially be used to treat COVID-19 and as a vaccine to prevent infection. It invested $55 million in the biotech, … La Fundación de Bill Gates ha confirmado a este diario la posesión de las acciones de Biontech. Bill Gates recently stated that he views Pfizer (NYSE: PFE) as the leader in the coronavirus vaccine race. Mainz, Germany. BioNTech and Pfizer had been working together on a flu vaccine since 2018, and in March, they agreed to collaborate on a coronavirus vaccine. When J&J dropped $30 billion into an Actelion buyout back in 2017, it hoped the biotech’s pipeline would add something fresh to the massive drugmaker’s slow-to-grow portfolio. The Motley Fool recommends Nasdaq and recommends the following options: long January 2021 $85 calls on Microsoft and short January 2021 $115 calls on Microsoft. → BeiGene, a pi­o­neer and dar­ling of the grow­ing US-Chi­na biotech crowd, was the sub­ject of a fe­ro­cious short re­port pub­lished by J Cap­i­tal on Thurs­day. The Department of Health and Human Services said late Thursday that it’s postponing a last-minute rule enacted by former President Trump’s HHS that would’ve required the FDA to review almost every one of its regulations, which would’ve diverted necessary resources away from the agency’s ongoing work on the pandemic. But not this, Jim Cramer on Chesapeake Energy filing for bankruptcy. Though a COVID-19 vaccine could certainly boost Pfizer's fortunes, the big drugmaker's future success doesn't depend on it. Eine der Firmen, die wir in unserem Corona-Spezial-Report genauer beleuchten konnte im September 2019 ein hohes 55 Millionen USD Investment von der Bill und Melinda Gates Foundation einsammeln. In a state­ment to the HKEX, BeiGene called the al­le­ga­tions “in­ac­cu­rate, un­found­ed and mis­lead­ing” as well as “bla­tant­ly false.”, “From its in­cep­tion, BeiGene has op­er­at­ed with an un­wa­ver­ing com­mit­ment to com­pli­ance, ethics, and in­tegri­ty,” it wrote. BioNTech has received funding from the Bill & Melinda Gates Foundation for … In 2015, the foundation committed to investing $52 million in CureVac (NASDAQ: CVAC). Microsoft and partners may be compensated if you purchase something through recommended links in this article. Merck has been in the FDA’s crosshairs over accelerated approvals for PD-(L)1 inhibitor Keytruda that have whiffed in confirmatory studies. BioNTech began developing its BNT162 COVID-19 vaccine program earlier this year. The Gates Foundation has been instrumental this year in funding coronavirus vaccine programs. Americans rely on mail carriers to send and receive their mail. They've donated over $45 billion to charitable organizations since 1994, with much of that amount going to the Bill & Melinda Gates Foundation. Al fin y al cabo, el magnate de internet ha fundido una parte importante de su fortuna en este campo, a través de la Fundación que codirige con su mujer, Belinda Gates. Frankfurt Die Mainzer Biotechfirma Biontech gewinnt mit der Bill-und-Melinda-Gates-Stiftung einen weiteren prominenten Forschungspartner und Finanzier. Ford just unveiled its 2021 tech-savvy pickup — here's what's new, Amazon looking to get into the self-driving car business buys startup for $1B, Economic outlook as more Americans file for unemployment, 5 items you can sell for additional income, 5 practical reasons to put purchases on credit, Disney World workers petition to delay reopening of theme park, 500 Delta staff have tested positive for COVID-19 and 10 have died. “Health care providers should review the authorized fact sheets for information on the use of the authorized mAb therapies against currently circulating viral variants.”. magic link that lets you log in quickly without using a password. With new approaches like home nursing, telehealth, direct-to-patient (DTP) drug shipments, and mobile sensors, DCTs are making it easier for patients to participate in trials, especially for those who live far away, are too sick to travel, or are too busy. Here are four coronavirus vaccine stocks that the Gates Foundation is betting on. The company is shooting for an initial indication of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. It invested $55 million in the biotech, with the potential for total funding to reach $100 million. Join thought-provoking conversations, … Bill Gates avait aidé à créer des institutions de taille planétaire et fait don de $55 milliards, quatre fois la dotation de l’influente Fondation Ford. Gates is probably correct in assessing Pfizer as the coronavirus vaccine leader. The former head of Merck’s global vaccine business was in the running for Frazier’s spot, an insider told Bloomberg back in 2019. Keith Speights owns shares of Microsoft and Pfizer. The global coronavirus pandemic catapulted the emerging field of decentralized clinical trials (DCTs) to the forefront of clinical research in a matter of months. Billionaire Bill Gates on Wednesday denied conspiracy theories that accuse the tech mogul and philanthropist of wanting to use coronavirus vaccines to implant tracking devices in people. All four of these coronavirus vaccine stocks owned by the Gates Foundation could be winners over the long term. MHRA made clear that the onsite inspections, which had been suspended since Jan. 5, will only occur at sites that have been notified at least two weeks in advance unless there are public health reasons that require shorter notice or unannounced inspections. Bill Gates and microchip claims Next, a conspiracy theory that has spanned the globe. No one has to tell Bill Gates to put his money where his mouth is. First Merck lost R&D MVP Roger Perlmutter at the end of last year. The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. Mavacamten is an oral allosteric modulator of cardiac myosin, intended to reduce contraction by the heart muscle. coronavirus vaccine Bill and Melinda Gates Foundation BioNTech Pfizer. Bill Gates puede presumir de ser una de las personas más ricas del mundo. “Based on a count cited in the SUNSET final rule, under the timeline and definitions provided in the final rule, over 7,000 sections of the Code of Federal Regulations promulgated by the Food and Drug Administration (FDA) are more than ten years old or would become more than ten years old during the first five years the rule would be in effect, representing over 95 percent of its current regulations,” HHS said in announcing the postponement. BioNTech wasn't the first German biotech to attract the attention of the Gates Foundation. Five Prime was nearing a readout on their Phase II trial for gastric cancer. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! One of those mid-stage pickups, MS candidate ponesimod, is now ready for showtime in a busy and growing MS market. Bill Gates recently stated that he views Pfizer (NYSE: PFE) as the leader in the coronavirus vaccine race. Actually, the foundation first bought a stake in Pfizer back in 2002 with the stated intention of "expand[ing] access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana Press, giving women in the developing world an affordable option.". BioNTech (pronounced bye-on-tech) was founded in the city of Mainz in 2008 by husband and wife duo Ugur Sahin and Ozlem Tureci. To­tal fund­ing un­der the deal could hit $100 mil­lion, via po­ten­tial grant fund­ing from the foun­da­tion, BioN­Tech said on Wednes­day. Just because you’re working from home doesn’t mean your boss can’t keep tabs on your every move. A Bill Gates SPAC connection. How you can save a million bucks for retirement. M it der Bill & Melinda Gates-Foundation hat das Mainzer Biotechnologieunternehmen Biontech einen weiteren namhaften Finanzier und Forschungspartner hinzugewonnen. one-time use only and expires after 24 hours. Friday, September 6, 2019, 09:00 Hrs [IST] BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, has signed an agreement with the Bill & Melinda Gates Foundation (the Gates … BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases ... -- Bill & Melinda Gates … I LEGAMI CON LA BILL AND MELINA GATES FOUNDATION ... BioNTech SE, German cancer treatment firm, downsized its offering Wednesday to raise … “Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19,” FDA said. The agreement involved cooperation on developing new mRNA techniques to treat cancer and HIV. Bill & Melinda Gates Foundation and Singapore’s . After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Neben einer neuen Form der Krebstherapie bietet Biontech auch Know-how zur Behandlung von HIV und Tuberkulose. The ac­qui­si­tion will help Zhe­jiang Ji­uzhou ce­ment its po­si­tion as a strate­gic sup­pli­er to No­var­tis, not­ed the re­port. CureVac listed its shares on the Nasdaq stock exchange in August 2020. It's not surprising that the Bill & Melinda Gates Foundation also owns shares of BioNTech. the leader in the coronavirus vaccine race, recently began a phase 2/3 clinical study. Nally is ending his nearly two-decade run at Merck to pursue a leadership opportunity at another company, though it’s not yet clear where. Vir's pipeline now includes several coronavirus-focused programs. Veuer’s Sean Dowling has more. The foundation's goal with its position in Vir was to "support the development of affordable and accessible HIV and TB prophylactic vaccine programs, and support the development of a new partner in the infectious disease space.". Both Sahin and … There's a pretty strong argument to be made that the coronavirus vaccine candidate that BioNTech and its partner Pfizer ( NYSE:PFE) are developing is the … ... Last year, the Bill & Melinda Gates … ", The Gates Foundation also owns shares of the big drugmaker. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Again, though, the nonprofit foundation didn't invest in the German biotech stock because of its coronavirus program. Bill Gates’ Stiftung investiert in Mainzer Firma. BioNTech is focused on combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. However, my view is that the best bets for investors among the group are Pfizer and BioNTech. *Stock Advisor returns as of August 1, 2020, Like us on Facebook to see similar stories, Newsom: All expected to be eligible for vaccine by May 1, Turkey pulls out of landmark treaty protecting women from violence, Jim Cramer on Johnson & Johnson entering phase 3 trial for coronavirus vaccine. The rest of BioNTech’s infectious disease candidates are in the preclinical stage. ENDPOINTS NEWSby John Carroll & team — all the news at 11:30am ET, EARLY EDITIONby Arsalan Arif — news and links at 7:15am ET, ENDPOINTS MANUFACTURINGWeekly biopharma manufacturing report, Thursdays at 2pm ET, ENDPOINTS WEEKLYRecaps the most important developments on Saturday 6am ET, ENDPOINTS FDA+Regulatory news and analysis for drug developers, Wednesday 2pm ET, → BeiGene, a pi­o­neer and dar­ling of the grow­ing US-Chi­na biotech crowd, was the sub­ject of a fe­ro­cious, Robert Bradway (Photographer: Scott Eisen/Bloomberg via Getty Images), MHRA chief executive June Raine speaks during a coronavirus briefing at 10 Downing Street, London, March 18, 2021 ((Tolga Akmen/Pool Photo via AP Images), by Arsalan Arif — news and links at 7:15am ET, Weekly biopharma manufacturing report, Thursdays at 2pm ET, Recaps the most important developments on Saturday 6am ET, Regulatory news and analysis for drug developers, Wednesday 2pm ET, BioN­Tech part­ners with Bill and Melin­da Gates Foun­da­tion, scor­ing $55M eq­ui­ty in­vest­ment; BeiGene brush­es off short at­tack, Top Five Rules for Suc­cess in De­cen­tral­ized Tri­als, Out­bid­ding 14 oth­ers and then them­selves: How Am­gen spent $2 bil­lion on a biotech that had been on the brink, FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study, A packed MS mar­ket is about to get busier as J&J's pones­i­mod en­ters the fray, UK drug reg­u­la­tor to restart in­spec­tions at the end of March with a fo­cus on so­cial dis­tanc­ing, Mer­ck breathes a sigh of re­lief as Keytru­da-Lenvi­ma com­bo aces con­fir­ma­to­ry study in en­dome­tri­al can­cer, FDA spells out how the Covid-19 vari­ants im­pact the ef­fec­tive­ness of Re­gen­eron, Eli Lil­ly mAb treat­ments, HHS post­pones re­view of over 95% of FDA’s reg­u­la­tions so crit­i­cal re­sources are not di­vert­ed from Covid-19, De­nied top job, Mike Nal­ly ex­its chief mar­ket­ing job at Mer­ck as the big C-suite shake­up con­tin­ues. The Motley Fool has a disclosure policy. Britain’s fresh agreement with Germany’s BioNTech and the Bill Gates-backed Pfizer netted 30 million doses of their joint mRNA vaccine, a first for … One of those speedy nods, a pairing with TKI inhibitor Lenvima from Eisai in endometrial cancer, has now scored a much-needed OS win to back up its case. Please note this link is one-time use only and is valid for only 24 hours. It had already made significant progress with this program when it announced a partnership with Pfizer in March. The FDA on Thursday afternoon updated its three fact sheets on the monoclonal antibody treatments from Eli Lilly and Regeneron, offering new data on the susceptibility of the SARS-CoV-2 variants originating in the UK, Brazil, South Africa, California and New York to each of the mAb therapies. Vir expects to initiate a phase 2 study of another COVID-19 antibody therapy, VIR-7832, later this year.